Shares of Gilead Sciences, Bristol-Myers Squibb, and Vertex Pharmaceuticals got a boost from clinical trial results and regulatory decisions.

Completed divestiture of China operations Uliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody) Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies…

Katie Stockton breaks down the charts in Bristol-Myers, J&J and Pfizer.

BRISTOL-MYERS Squibb-backed Zenas BioPharma has filed to go public in the United States, a regulatory filing showed on Thursday, underscoring improving investor appetite for new listings. The US initial public offering (IPO) market is in the early innings of a recovery on hopes of potential interest-rate cuts and lower market volatility. Zenas BioPharma, an immunology and inflammation focused biopharma company, said it has raised $358.3 million from investors since its inception. The company''s investors include Tellus BioVentures, Fairmount, Norwest Venture Partners, Enavate Sciences and Bristol-Myers Squibb. The firm''s losses widened to $65.8 million for the six months ended June 30, compared with $48.1 million, a year earlier. It did not reveal the number of shares it planned to sell and the proposed price range. The company expects its shares to trade on the Nasdaq Global Market under the ticker symbol "ZBIO." Morgan Stanley, Jefferies, Citigroup and Guggenheim Securities are the underwriters.

No summary available.

NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) announced that the U.S. Food and Drug Administration has accepted the supplemental Biologics License Application or sBLA for Opdivo (nivolumab)…

Bristol-Myers Squibb (BMY) liver cancer drug Opdivo plus Yervoy is being reviewed by the FDA for expanded labeling as a first-line therapy. Read more here.

Promising news for HCC patients: FDA accepts Bristol Myers Squibb''s application for Opdivo-Yervoy combo as potential first-line treatment. Learn about the improved survival rates and what this means for liver cancer care.

Bristol Myers Squibb''s application for follicular lymphoma therapy approved by European Medicines Agency for label expansion as third-line treatment.

NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Company (BMY), Monday announced that the European Medicines Agency has validated its Type II variation application to expand the indication for Breya…